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Pulmonary arterial hypertension is a disease affecting the pulmonary vasculature leading to an 
increase in pulmonary vascular resistance and consequently pulmonary artery pressure. Despite of 
the disease being in the lungs, clinical outcome in PAH is mainly determined by RV function.1 While 
with the introduction of therapies pulmonary vascular resistance can be reduced, patients still 
progress towards right heart failure2, which is the main cause of death in PAH.3 Therefore, enhanced 
insight into RV function and adaptation is essential in PAH patients and may provide new tools to 
identify, at an early stage, patients at risk for developing right heart failure.  
Recently, load-independent assessment of RV systolic and diastolic function, by means of pressure-
volume analysis, has become possible in PAH patients due to the development of single-beat 
methods.4–6 Pressure-volume analysis not only allows load-independent assessment of RV function, 
but also the characterization of the arterial load.7–9 A more detailed evaluation of RV function is 
therefore available in PAH patients, allowing the separation of the different factors (RV preload, 
afterload, RV contractile function, RV diastolic function) that may be additive to the presently used 
RV function parameters, such as RV ejection fraction, cardiac output or mean right atrial pressure that 
are both RV and load dependent. As such, in the first part of the present thesis, we aimed to describe 
load-independent RV systolic and diastolic function and its clinical relevance in a large cohort of PAH 
patients using single-beat pressure-volume analysis and revealed the following: 
 
 For an accurate assessment of load-independent RV systolic function (by means of end-systolic 
elastance) RV pressures and volumes are required. Volume alone gives inadequate information 
(CHAPTER 3).  
 A reduced RV-arterial coupling ratio, reflecting a reduced RV systolic adaptation to arterial load, 
is discriminative at baseline and in treated patients for disease progression (CHAPTER 4).  
 RV diastolic stiffness is related to clinical progression both at baseline and in treated patients. In 
patients with a long survival, RV diastolic stiffness is explained by increased wall thickness, while 
in patients with a short survival RV diastolic stiffness is not explainable by wall thickness alone, 
suggesting that intrinsic myocardial processes such as fibrosis and sarcomeric stiffening play a 
distinctive role in different disease stages (CHAPTER 5). 
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In the second part of this thesis we aimed to get more insight into the group of IPAH patients that is 
characterized by advanced age, lower diffusion capacity for carbon monoxide (DLCO) and worse 
prognosis. These patients are increasingly seen in pulmonary hypertension referral centers10,11, and a 
more detailed description of this subgroup is needed. By using DLCO as a tool to identify patients as a 
subgroup within IPAH, we were able to show that: 
 A severely reduced DLCO is related to advanced age and greater tobacco exposure. This suggests 
that a severe reduction in DLCO identifies a subtype of IPAH in which the disease is likely related 
to smoking. Furthermore, we confirmed that patients with a severely reduced DLCO have a worse 
survival that is related to age, gender and the presence of coronary disease (CHAPTER 6). 
As a continuation of this study, we studied in greater detail at the difference in DLCO between non 
BMPR2- and BMPR2-mutation carriers, as it has been suggested that these patients have different 
vascular processes underlying their pulmonary hypertension. By using DLCO as a tool to describe the 
alveolar-capillary structure, we were able to show that: 
 In non-smoking patients the DLCO is more preserved in patients with a BMPR2 mutation when 
compared to patients without the mutation, suggesting a distinct vascular process in BMPR2 
mutation carriers (CHAPTER 7).  
 
Future directions - Part I  
 
Physiology of Right Ventricular Function & Adaptation in Pulmonary Arterial 
Hypertension 
 
Prognostic value & clinical applicability of pressure-volume analysis in PAH  
There are several questions that remain to be answered regarding load-independent assessment of 
RV function by means of pressure-volume analysis in PAH. First of all, in the present thesis we show 
that RV-arterial coupling and RV diastolic stiffness relate to survival. Future studies are needed to 
compare RV-arterial coupling and RV diastolic stiffness with known prognostic parameters such as 
right atrial pressure, cardiac output and RV ejection fraction. Studies with large patient populations 
and a greater number of events will allow a multivariate statistical analysis in order to assess whether 
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RV-arterial coupling and/or RV diastolic stiffness at baseline, or during follow-up, plays an additive 
role in predicting clinical outcome in PAH patients.  
 
Larger and longitudinal studies are warranted to address the additive role of pressure-volume 
analysis. Yet, due to the invasiveness of pressure-volume analysis, this type of analysis is of limited 
clinical value when it comes to applicability. For that reason, noninvasive measures that reflect RV 
systolic and diastolic function in a load-independent matter are needed to make the assessment of 
load-independent RV systolic and diastolic function in a longitudinal way, and in larger patient 
populations, possible. Ideally, these non-invasive methods are largely load-independent and should 
be applicable not only in PAH patients, but also in healthy controls. Possible noninvasive methods that 
need to be validated for the RV and assessed for its load-independency are: myocardial acceleration 
during isovolumic contraction by tissue Doppler velocity imaging (systolic function)12, and RV diastolic 
wall strain.13,14 RV-arterial coupling is noninvasively assessed in literature by dividing end-systolic 
volume by stroke volume.15 Although used frequently, this method has not been validated in PAH and 
has been shown to be based on the assumption that cannot hold in PAH patients, leading to an 
underestimation of RV end-systolic elastance and thus RV-arterial coupling, as is shown in CHAPTER 
3 of this thesis.  
 
FIGURE 8.1. Schematic 
overview of our findings 
and hypotheses on changes 
in RV function over time. An 
increase in afterload (Ea) 
stimulates the hypertrophic 
process. An increased RV 
mass then results in 
enhanced RV systolic 
function (Ees) and RV 
diastolic stiffness (Eed). In 
this stage of adaptive 
remodeling, RV-arterial 
coupling is maintained 
(Ees/Ea) and no dilatation 
has occurred yet. Eed is 
increased proportional to 
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relative wall thickness. In patients with a maladapted or failing RV, RV-arterial coupling is reduced, possibly because RV Ees cannot 
further increase due to a halted hypertrophic response* or RV diastolic stiffening. The RV dilates and there a signs of fibrosis and/or 
sarcomeric stiffening as Eed is further and disproportionally increased to relative wall thickness**. PA: pulmonary arteriole; LV: left 
ventricle.  
 
Mechanisms of RV diastolic stiffness & the effect of reducing it 
We observed in CHAPTER 5 that RV diastolic stiffness is disproportionately increased in progressive 
PAH patients, while in stable patients, the ratio between RV diastolic stiffness and relative wall 
thickness is maintained at a normal level. We therefore hypothesize that RV diastolic stiffening as a 
result of hypertrophy alone is a good sign, while RV diastolic stiffening due to intrinsic RV wall changes, 
such as fibrosis or sarcomeric stiffening, is not a beneficial sign and occurs mainly in patients who are 
transitioning from adaptative remodeling to RV failure. Therefore, it could be of great importance to 
assess the presence of fibrosis and sarcomeric stiffening in PAH patients. However, the relation 
between hypertrophy and RV diastolic stiffening has never been described in literature, as taking RV 
tissue from PAH patients during disease progression is contraindicated due to the high risk of bleeding 
or rupture of the RV myocardium.16 Consequently, the presence of fibrosis and/or sarcomeric 
stiffening cannot be assessed in the human and our hypothesis not investigated. We therefore 
propose to establish a method to distinguish hypertrophy, fibrosis and sarcomeric stiffening.  
There are two directions that can be taken to establish such a method. First, in a preclinical setting 
the relation between the different tissue characteristics and RV diastolic stiffness can be assessed by 
measuring hypertrophy, the extent of fibrosis and sarcomeric stiffening in animal models with stable 
and progressive PAH. In cardiomyocytes taken from these different PAH models, total passive-tension 
relations, titin-based (sarcomeric stiffening) and collagen-based (fibrosis) passive-tension relations 
can be derived using extraction and degradation techniques.17 As such, the contribution of the 
different tissue characteristics to RV diastolic stiffness can be determined.  
The other direction is set in patients. In patients, cardiac MRI could be used to assess the different 
tissue characteristics. Hypertrophy can be assessed with cardiac MRI by measuring RV mass. Fibrosis 
can be assessed by means of T1 and T2 relaxation times. These times vary significantly from one type 
of tissue to another, but also within the same tissue depending on the presence of fibrosis.18 
Gadolinium contrast agents can further increase the visibility of fibrosis.18 Whether these methods 
are sensitive enough to detect relevant differences in the amount of fibrosis is unclear and should be 
investigated. For sarcomeric stiffening there is no method currently available, as the resolution of 
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currently used imaging techniques doesn’t allow visualization of sarcomeres within the cardiomyocyte 
for being able to measure its function.   
 
In our recently published study on RV diastolic function in PAH and in the present thesis we 
demonstrate the clinical relevance of RV diastolic stiffness in PAH.6 Targeting RV diastolic stiffness 
may therefore be beneficial and may improve survival. In animal models of PAH, it has been shown 
that a reduction in RV diastolic stiffening can be achieved by β-blocker therapy.19 However, β-blocker 
therapy is currently not recommended in patients with PAH due to its side effects.19 Recently, a report 
of an open-label pilot study of β-blocker therapy in six patients with PAH showed that treatment was 
safe.20 Results of randomized, placebo-controlled trials are on the way and should answer the 
question whether β-blocker therapy improves important clinical parameters that are related to 
outcome.  
 
Evaluation of changes in RV function over time 
How the RV shifts from adaptive remodeling to right heart failure is currently not well understood. 
Several cellular/molecular process have been postulated to play a role in this transition.16 However, 
how at the ventricular level RV function changes over time has never been revealed. Based on the 
results presented in the present thesis, we can conclude that in stable disease, a preserved RV-arterial 
coupling relates with normal RV volumes. However, it remains unknown whether this preserved RV-
arterial coupling in stable disease is followed first by a reduction in RV-arterial coupling before RV 
dilatation occurs, a hypothesis postulated in literature.21  
We hypothesize that the following sequence of events occurs (see also FIGURE 8.1): first, in adaptive 
remodeling the RV is hypertrophied in response to the increased pressure resulting from the increased 
resistance expressed as arterial elastance. Diastolic wall stress is normalized and no dilatation has 
occurred. Due to hypertrophy, both RV end-systolic elastance and RV diastolic stiffness are increased. 
Consequently, RV-arterial coupling is preserved. On the way to maladaptive remodeling and right 
heart failure, the process of hypertrophy is halted by limitations in capillarization and possibly other 
mechanisms currently unknown.16 In addition, long-term neurohormonal activation may lead to an 
additional increase in RV diastolic stiffness attributable to sarcomeric stiffening. This may result in a 
reduced contractile function.16 The combination of both halted hypertrophy and impaired contractile 
function of the cardiomyocytes will then lead to a reduction in RV end-systolic elastance and thus 
worse RV-arterial coupling. RV dilatation will then occur and will lead to an enhancement of RV 
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myocyte contractile force through the Frank-Starling mechanism.22 However, excessive dilatation will 
stretch the cardiomyocytes too much, leading to a decrease in contractile force. In maladaptive 
remodeling, an increase in RV end-diastolic wall stress, RV fibrosis, further RV diastolic stiffening and 
impaired contractility will put the RV in a vicious circle of worsening of function leading to right heart 
failure and death.    
Pressure-volume analysis and cardiac MRI performed on a regular basis (for example once a year) in 
PAH patients, from time of diagnosis until clinical deterioration and death, will give more insight into 
the sequence of RV functional changes that occur when the RV shifts from adaptive remodeling to 
right heart failure. 
 
Future directions - Part II  
 
Pulmonary diffusion capacity in patients with pulmonary arterial hypertension 
 
To enhance insight into IPAH patients with a low diffusion capacity 
Over the past decades knowledge on pulmonary hypertension has considerably increased. Several 
epidemiological studies have revealed the clinical characteristics of different groups of PAH and their 
survival.23,24 Based on these studies the image of the IPAH patient is presented as being young, female, 
and without comorbidities. As a consequence of these earlier registries, IPAH is usually considered a 
homogenous disease. However, recent registries give a different image of the IPAH patient today.10,11 
Patients with IPAH are now older and have more comorbidities, posing the idea that a different 
phenotype is emerging. Nevertheless, currently there are no good tools to assess these different 
phenotypes. By using DLCO in IPAH patients in the present thesis, we provided a tool to portray a 
subgroup of patients with a severely reduced DLCO that is characterized by a higher age, a higher 
tobacco exposure, and more comorbidities (CHAPTER 6), suggesting that the pulmonary hypertension 
in these patients is possibly related to smoking or to the comorbidities described. To obtain more 
insight into the different phenotypes of IPAH patients, additional assessments are required. These 
assessments, as described below, may lead to a better clinical classification of patients and 






FIGURE 8.2 Schematic overview of the 
findings on DLCO. Idiopathic PAH patients 
that present with a severely reduced DLCO 
are more likely to be of advanced age and 
have a high tobacco exposure. They have 
worse survival that is related to age, sex and 
coronary disease (Chapter 6). A BMPRII-
mutation is only found in patients with a 













Assessing occult left ventricular diastolic dysfunction  
Coronary artery disease was more frequently present in patients with a severely reduced DLCO. As 
such, occult left ventricular (LV) diastolic dysfunction could be present in this group of patients. In the 
present thesis, we were not able to assess the presence of occult LV diastolic dysfunction in this group 
of patients. Therefore, future studies are needed to do so. This could include the measurement of 
pulmonary capillary wedge pressure (PCWP) during fluid administration or exercise in all IPAH patients 
or in for example IPAH patients who present with a resting PCWP >10 mmHg.25 All patients should 
then be treated like IPAH patients, with careful follow-up registrations of pulmonary hemodynamics, 
including PCWP, RV and LV function. This to assess whether there are differences in PAH-treatment 
responses between IPAH patients with a normal PCWP after fluid administration and IPAH patients 
with an increase in PCWP >15 mmHg after fluid administration. This could give information on 
whether IPAH patients with occult LV diastolic dysfunction (defined by a PCWP >15 mmHg after fluid 
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administration) require a different therapeutic strategy and should possibly be classified within group 
II of the Nice classification.26  
 
Assessing mild interstitial or emphysematous lung disease 
In addition to the additional analysis of patients with a severely reduced DLCO described above, a 
more detailed evaluation of high resolution CT scans in this group could give more information on the 
presence of mild interstitial abnormalities or emphysematous changes. High resolution CT scans 
should not only be analyzed at baseline, but also during follow-up to assess possible progression of 
mild abnormalities or the emergence of new abnormalities during the disease of PH. Also, as in the 
assessment of occult LV diastolic dysfunction described above, treatment response should be carefully 
documented to determine whether patients with lung abnormalities exhibit a different response 
compared to patients without abnormalities. 
 
Assessing pulmonary vasculopathy 
Pathological analysis is further needed to assess the type of vasculopathy present and to determine 
whether this is different from IPAH patients with a more preserved DLCO. This should include the 
assessment of plexiform lesions, intima, media and adventitia thickening, interstitial inflammation, 
fibrotic changes, and the presence of venous lesions.27 Pathological analysis may further reveal why 
DLCO is severely reduced in these patients. By studying the alveolar-capillary structures, by for 
example electron microscopy, one could reveal thickening of the alveolar-capillary membrane not 
detectable by current high-resolution CT scans. Pathological analysis may also show differences in 
alveolar-capillary structures between BMPR2-mutation carriers and non-carriers, as is hypothesized 
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